JNJ Jun 2025 140.000 put
| Previous Close | 2.3600 |
| Open | 2.8500 |
| Bid | 1.9700 |
| Ask | 2.7200 |
| Strike | 140.00 |
| Expire Date | 2025-06-20 |
| Day's Range | 2.8500 - 2.8500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1.07k |
ZacksFDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis
With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.
Insider MonkeyIs Johnson & Johnson (JNJ) the Best Defensive Stock According to Reddit?
We recently compiled a list of the 10 Best Defensive Stocks According to Reddit. In this article, we will look at where Johnson & Johnson (NYSE:JNJ) stands against the other defensive stocks. September is typically the worst month for the markets, however with a much anticipated rate cut, 2024 might be a different story. The current […]
PR NewswireTREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease
Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic disease of the large intestine in which the lining of the colon becomes inflamed. TREMFYA® is the first and only approved fully-human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23. IL-23 is a cytokine
